Balaglitazone
产品说明书
 |
同义名 : | DRF 2593; NN 2344; NNC-61-2344; NNC-61-0645 |
| CAS号 : | 199113-98-9 | |
| 货号 : | A117326 | |
| 分子式 : | C20H17N3O4S | |
| 纯度 : | 99%+ | |
| 分子量 : | 395.432 | |
| MDL号 : | MFCD09837808 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(265.53 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Balaglitazone is a selective partial agonist of PPARγ with an effective concentration 50 (EC50) of 1.351 μM[1]. Within the concentration range of 5-100 μM, Balaglitazone exhibits uniform cytotoxicity against both K562 and K562/DOX cells. It moderates the toxicity of doxorubicin in these cells, showing IC50 values of 0.117 μM for K562 and 0.53 μM for K562/DOX cells. It is also effective in counteracting multidrug resistance (MDR) in K562/DOX cells. At a concentration of 25 µM, Balaglitazone enhances Rh123 accumulation in K562/DOX cells without affecting MFI in K562 cells. It suppresses P-gp expression in K562/DOX cells through the upregulation of PTEN, a process that can be reversed by PTEN inhibition[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.53mL 0.51mL 0.25mL |
12.64mL 2.53mL 1.26mL |
25.29mL 5.06mL 2.53mL |
| 参考文献 |
|---|